News
12-16-2009, 02:42 AM
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that an overall survival benefit would be the most influential factor for three-quarters of surveyed European oncologists in their decision to prescribe a novel agent ahead of Avastin for the treatment of breast cancer.
More... (http://www.news-medical.net/news/20091216/Avastin-may-lose-significant-patient-share-to-Sanofi-Aventis-BSI-201-according-to-report.aspx)
More... (http://www.news-medical.net/news/20091216/Avastin-may-lose-significant-patient-share-to-Sanofi-Aventis-BSI-201-according-to-report.aspx)